Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about Tau protein / microtubule-associated pathway: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
| Target | Relation | Type | Str |
|---|---|---|---|
| No outgoing edges | |||
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Noradrenergic-Tau Propagation Blockade | 0.510 | neurodegeneration | Sleep disruption as cause and consequenc |
| Selective Tau Kinase Inhibition in Vulnerable Neuronal Subty | 0.504 | neurodegeneration | Cell type vulnerability in Alzheimers Di |
| Locus Coeruleus-Hippocampal Circuit Protection | 0.480 | neuroscience | Circuit-level neural dynamics in neurode |
| HSP90-Tau Disaggregation Complex Enhancement | 0.442 | Alzheimer's Disease | Tau propagation mechanisms and therapeut |
| Synaptic Vesicle Tau Capture Inhibition | 0.340 | Alzheimer's Disease | Tau propagation mechanisms and therapeut |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-04 | 15 hypotheses Top: 0.716
neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.557
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| Tau Spreading Network Mapping via Spatial Transcriptomics in PSP | clinical | Neurodegeneration | 0.400 | 0.50 | mouse | proposed | $520,000 |
| 4R-Tau Targeting Therapies for PSP and CBS | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Tau Propagation Causality Test — Does Tau Spread Drive Neurodegenerati | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Tau Co-Pathology in DLB Clinical Heterogeneity | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Levodopa Response Determinants in PSP — Biomarker-Guided Prediction St | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Non-Dopaminergic Neurotransmitter Degeneration in PD - Experiment Desi | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Tau Pathology Initiation Zone Identification | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $5,460,000 |
| PSP and CBS Biomarker Validation Study | clinical | ALS | 0.400 | 0.50 | human | proposed | $7,500,000 |
| Alpha-Synuclein Staging and Spreading in DLB — Spatial Propagation Map | validation | Parkinson's Disease | 0.400 | 0.50 | cell_line | proposed | $160,000 |
| Pre-Symptomatic Tau Detection in MAPT Mutation Carriers | clinical | ALS | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Anti-Tau Antibody vs ASO/Gene Therapy — Comparative Efficacy in 4R-Tau | validation | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $170,000 |
| Tau PET Pattern as Therapeutic Response Predictor in 4R-Tauopathy | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $7,500,000 |
| Prion Strain Diversity and Selective Vulnerability | clinical | Alzheimer's Disease | 0.400 | 0.50 | mouse | proposed | $400,000 |
| Proteasome-Ubiquitin System Dysfunction Validation in Parkinson's Dise | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| CBS vs PSP Phenotype Determinants — Single-Nucleus Multi-Omics Study | validation | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $160,000 |
| Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Trials Have N | clinical | ALS | 0.400 | 0.50 | human | proposed | $7,500,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Machine Learning and Novel Biomarkers for the Diagnosis of Alzheimer's Disease. [PMID:33803217] | Chang CH, Lin CH, Lane HY | Int J Mol Sci | 2021 | 1 |
| Ischemia-induced upregulation of autophagy preludes dysfunctional lysosomal stor [PMID:33111641] | Zhang X, Wei M, Fan J, Yan W, Zha X, Son | Autophagy | 2021 | 1 |
| Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 po [PMID:31227597] | Snyder AG, Hubbard NW, Messmer MN, Kofma | Sci Immunol | 2019 | 1 |
| Effect of etching with potassium hydrogen difluoride and ammonium hydrogen diflu [PMID:31068549] | Akazawa N, Koizumi H, Nogawa H, Kodaira | Dent Mater J | 2019 | 1 |
| Synapse formation in the brain can be enhanced by co-administering three specifi [PMID:29031899] | Wurtman RJ | Eur J Pharmacol | 2017 | 1 |
| Engineered AAVs for efficient noninvasive gene delivery to the central and perip [PMID:28671695] | Chan KY, Jang MJ, Yoo BB, Greenbaum A, R | Nat Neurosci | 2017 | 1 |
| The Pediatric Imaging, Neurocognition, and Genetics (PING) Data Repository. [PMID:25937488] | Jernigan TL, Brown TT, Hagler DJ Jr, Aks | Neuroimage | 2016 | 1 |
| Gigantol: a principal bioactive constituent of Dendrobium species-multi-target m [PMID:40939944] | Shi S, Zhu C, Xu J, Sui Q, Zhu S, Zhang | Journal of ethnopharmacology | 2026 | 0 |
| Biomimetic cancer cell membrane-coated liposomal nanocarriers loaded with silibi [PMID:41585438] | Yao J, Sun Q, Zhang X, Yang D, Wu H et a | Mater Today Bio | 2026 | 0 |
| Exploring synergistic therapeutic potential of Erlotinib and artemisinin in non- [PMID:41672289] | Suleman F, Khan T, Alshehade SA, Ali M, | Clin Chim Acta | 2026 | 0 |
| Desidustat's cardioprotective mechanisms in heart failure: a network pharmacolog [PMID:41946767] | Sadiqbasha MF, Gunasekaran A, Thirulokac | Sci Rep | 2026 | 0 |
| PRMT5-Mediated Arginine Methylation of HSP90AA1 Drives Esophageal Squamous Cell [PMID:41966513] | Chen T, Lv Y, Wang J, Yuan Y, Xu K et al | Cancer Lett | 2026 | 0 |
| Methyl-4-hydroxybenzoate induces osteoporosis via the AKT1/LC3B/Beclin1 autophag [PMID:41740552] | Fu F, Wang W, Li Y, Shi S, Huang J, Liu | Ecotoxicology and environmenta | 2026 | 0 |
| Chronic Thermal Stress During Early Zebrafish (Danio rerio) Development Induces [PMID:41793424] | Adzijovski M, Schultz AG, Oxley APA, Ber | Fish physiology and biochemist | 2026 | 0 |
| α-Glucosidase inhibitor: identifying key targets and mechanisms in type 2 diabet [PMID:41907120] | Garg SS, Vijh D, Gupta P, Gupta J, Malik | 3 Biotech | 2026 | 0 |
| Elucidating the mechanisms of aristolochic acid-induced upper tract urothelial c [PMID:41780445] | Liu T, Yao Y, Xu Y, Zhang H, Sun L, Zhan | Computational biology and chem | 2026 | 0 |
| A Study on the Mechanism of Acetyl Tributyl Citrate-Induced Infertility Toxicity [PMID:41898778] | Sun X, Chen P, Han Y, Du Y, Sun S, Miu J | International journal of molec | 2026 | 0 |
| Predicting onset of symptomatic Alzheimer's disease with plasma p-tau217 clocks. [PMID:41714746] | ["Petersen Kellen K", "Mil\u00e0-Alom\u0 | Nature medicine | 2026 | 0 |
| A minimally invasive dried blood spot biomarker test for the detection of Alzhei [PMID:41491101] | Huber H, Montoliu-Gaya L, Brum WS, Vávra | Nat Med | 2026 | 0 |
| Plasma pTau 217/β-amyloid 1-42 ratio for enhanced accuracy and reduced uncertain [PMID:41562409] | Benina N, Buitrago L, De Simone FI, Radw | Brain | 2026 | 0 |
Multi-agent debates referencing this entity
active · Rounds: 4 · Score: 1.00 · 2026-04-12
active · Rounds: 4 · Score: 0.59 · 2026-04-06
active · Rounds: 4 · Score: 0.54 · 2026-04-04